Drug combination suppresses growth of late-stage prostate cancer tumors
Low doses of metformin, a widely used diabetes medication, and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, according to a new study published in the Journal of Biological Chemistry (2015; 290:2024-2033). The study used cultured prostate cancer cells and mouse models of prostate cancer.
Prostate cancer causes the second-highest number of cancer-related deaths in men in the United States, and methods of treating advanced prostate cancer are limited.
Xiaoqi Liu, PhD, associate professor of biochemistry and cancer research at Purdue University in West Lafayette, Indiana, and fellow researchers found that the drugs metformin and BI2536 can work together to suppress the spread of prostate cancer that resists all other available treatments, potentially prolonging patients' lives.
"We've found a promising way to treat late-stage prostate cancer," Liu said. "By combining low levels of two well-tolerated drugs, the progression of this disease could be significantly delayed. Completely curing the cancer at the advanced stage is pretty much impossible, but this treatment might manage it for a while. That's exciting."
A number of treatments exist for the earlier stages of prostate cancer, which grows slowly compared with many other cancers. Because prostate cancer cells need the male sex hormone androgen to develop, one way to treat the disease is to suppress androgen, a process known as castration.
If the cancer continues to spread, the patient often undergoes chemotherapy. As a last resort, drugs that block the synthesis of androgen by prostate cancer cells can be used, but these medications only extend a patient's lifespan for several months.
New approaches to treating the most persistent forms of prostate cancer are urgently needed, Liu said.
Castration can disrupt the body's metabolism and lead to insulin resistance, which also can stimulate the production of androgen. The cancer will spread until both of these side effects are stopped, Liu said.
Previous studies showed that metformin, which is an inexpensive, antidiabetes drug that has been commonly used for more than 40 years, is particularly potent to prostate cancer tumors.
This study found that a combination of low levels of metformin and BI2536, a drug that stifles the activity of Plk1, could work in tandem to slow the growth of prostate tumors too advanced for current treatments by promoting the self-destruction of cancer cells and preventing androgen synthesis.
The drugs did not impact healthy prostate cells, a key finding, Liu said. "Ideally, cancer therapy will have minimal effects on normal cells."
Because metformin helps regulate metabolism, it may reverse some of the metabolic damage caused by castration, he said.
The researchers tested the drugs in a classical cell culture assay of prostate cancer cells and in advanced prostate tumors in mice. Low concentrations of the drugs significantly slowed the development of cancer in both trials. The mice tumors were grown from the tumor cells of a late-stage prostate cancer patient, suggesting that the treatment would prove effective in humans.
"Those results were amazing," Liu said. "These are the first data we've generated from a real patient, so I was almost jumping in the air when I saw that it worked."